AstraZeneca plc vs ABRDN Physical Gold Shares ETF — how do they compare? AstraZeneca plc trades at $158.4 (market cap $248.14B), while ABRDN Physical Gold Shares ETF trades at $42.02. The key difference: AstraZeneca plc pays a 2.01% dividend while ABRDN Physical Gold Shares ETF pays none, and ABRDN Physical Gold Shares ETF is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.
| AZN | SGOL | |
|---|---|---|
Market Cap | $248.14B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $209.48 | $51.41 |
52-Week Low | $147.06 | $31.61 |
Enterprise Value | $275.41B | — |
Dividend Yield | 2.01% | — |
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
SGOL, a US-listed gold ETF, trades at $41.91, up 0.26% today, with a bullish technical signal from moving averages but bearish oscillators. Recent news highlights gold's strength amid cooling US inflation and central bank demand, with spot gold reaching $4,438/oz on August 12, 2026. The ETF lacks fundamental ratios like P/E and P/B, as it tracks physical gold, not a company with earnings.
The outlook for SGOL is positive, driven by gold's safe-haven appeal and supportive macroeconomic factors, but risks include Fed policy shifts and gold price volatility. Analyst sentiment is mixed, with technical indicators suggesting caution near overbought levels.
Trailing returns across standard periods
Latest headlines on both assets
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →